Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
AFT Leaves X Over AI-Generated Images of Minors 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
NEW YORK, March 31, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc. (NASDAQ:RGLS) securities between January 21, 2016 and June 27, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/regulus-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) patients treated with its experimental product RG-101 were at increased risk of contracting jaundice; (ii) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, Regulus’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/regulus-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
